Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Jul 6;11(7):e0156489.
doi: 10.1371/journal.pone.0156489. eCollection 2016.

Specificity of Genetic Biomarker Studies in Cancer Research: A Systematic Review

Garrett Green  1 , Ruben Carmona  1 , Kaveh Zakeri  1 , Chih-Han Lee  1 , Saif Borgan  1 , Zaid Marhoon  1 , Andrew Sharabi  1 , Loren K Mell  1
Affiliations

Specificity of Genetic Biomarker Studies in Cancer Research: A Systematic Review

Garrett Green et al. PLoS One. .

Abstract

As genetic information becomes more readily available, there is increasing demand from both patients and providers to develop personalized approaches to cancer care. Investigators are increasingly reporting numbers of studies correlating genomic signatures and other biomarkers to survival endpoints. The extent to which cancer-specific and non-specific effects are reported in contemporary studies is unknown. In this review of 85 high-impact studies associating genetic biomarkers with cancer outcomes, 95% reported significant associations with event-free survival outcomes, yet less than half reported effects on a cancer-specific endpoint. This methodology leaves open the possibility that observed associations are unrelated to cancer.

PubMed Disclaimer

Conflict of interest statement

Competing Interests: The authors have declared that no competing interests exist.

Figures

Fig 1
Fig 1. Flow diagram of exclusion criteria.
Fig 2
Fig 2. Histogram of (A) All Endpoints and (B) Primary Endpoints Reported.
See this image and copyright information in PMC

References

    1. Kim C, Taniyama Y, Paik S. Gene-expression-based prognostic assays for breast cancer. Nat Rev Clin Oncol. 7, 340–7, 2010. 10.1038/nrclinonc.2010.61 - DOI - PubMed
    1. Van 't veer L, Dai H, Van de vijver M, He Y, Hart A, Mao M, et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature. 415, 530–6, 2002. - PubMed
    1. Kelloff G, Sigman C. Cancer biomarkers: selecting the right drug for the right patient. Nat Rev Drug Discov. 11, 201–14, 2012. 10.1038/nrd3651 - DOI - PubMed
    1. Chibon F. Cancer gene expression signatures—the rise and fall?. Eur J Cancer. 49, 2000–9, 2013. 10.1016/j.ejca.2013.02.021 - DOI - PubMed
    1. Sotiriou C, Piccart M. Taking gene-expression profiling to the clinic: when will molecular signatures become relevant to patient care? Nature Review Cancer. 7, 543–553, 2007 - PubMed

Publication types

Substances